Nebivolek (Nebivolol Hydrochloride)

Nebivolol, the active ingredient in Nebivolek, is a β1‑selective beta‑blocker presented as an oral tablet for oral use. It is indicated for the management of hypertension and chronic heart failure in adult patients. It offers a favorable hemodynamic profile by promoting vasodilation through nitric oxide release, which can improve tolerability compared with non‑selective beta‑blockers.\n\nGNH India supplies Nebivolek as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with EU quality standards and is manufactured under strict Good Manufacturing Practices, ensuring consistent potency and safety for patients.

Nebivolol is a β1‑selective beta‑blocker used to treat cardiovascular conditions related to high blood pressure and cardiac dysfunction.\n- Hypertension: reduces systolic and diastolic blood pressure, decreasing cardiovascular risk.\n- Chronic heart failure: improves left ventricular ejection fraction and reduces symptoms of fluid overload.\n- Left ventricular systolic dysfunction: enhances cardiac output and may delay disease progression.

Nebivolol may be associated with a range of adverse reactions, which are categorized by frequency.\n\nCommon Side Effects:\n- Headache\n- Dizziness or light‑headedness\n- Fatigue or tiredness\n- Nasal congestion\n- Nausea\n\nSerious or Rare Side Effects:\n- Severe bradycardia\n- Marked hypotension\n- Heart block or AV conduction disturbances\n- Bronchospasm in patients with reactive airway disease\n- Allergic reactions such as rash or angioedema\n- Hepatic enzyme elevations

When prescribing Nebivolol, clinicians should consider several precautionary measures to ensure safe use.\n- Blood pressure monitoring: check baseline and periodic readings to avoid excessive hypotension.\n- Cardiac function assessment: evaluate heart rate and ECG, especially in patients with conduction disorders.\n- Asthma or COPD caution: use with care as β‑blockade may precipitate bronchospasm.\n- Concomitant β‑blocker use: avoid combining with other β‑blockers to prevent additive effects.\n- Renal or hepatic impairment: dose adjustment may be required in moderate to severe dysfunction.\n- Store at room temperature: keep in the original container, protect from moisture and light.

Nebivolol can interact with other medicines, altering its efficacy or safety profile.\n\nMajor Interactions (Avoid):\n- Combined use with other β‑blockers: may cause excessive bradycardia and hypotension.\n- Co‑administration with non‑dihydropyridine calcium channel blockers (verapamil, diltiazem): increases risk of cardiac conduction delays.\n- Strong CYP2D6 inhibitors (paroxetine, fluoxetine, quinidine): raise nebivolol plasma concentrations.\n\nModerate Interactions (Monitor Closely):\n- Diuretics (thiazides, loop diuretics): additive blood‑pressure lowering effect, monitor for dehydration.\n- ACE inhibitors or ARBs: may enhance antihypertensive effect, watch for symptomatic hypotension.\n- Antidiabetic agents (insulin, sulfonylureas): nebivolol can mask hypoglycaemia symptoms, require glucose monitoring.